» Articles » PMID: 1480520

Tests of Adipsia and Conditioned Taste Aversion Following the Intrahypothalamic Injection of Amylin

Overview
Journal Peptides
Specialty Biochemistry
Date 1992 Sep 1
PMID 1480520
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Intrahypothalamic injection of amylin (AMY) was shown to reduce the intake of rat chow and water for 8 and 4 h, respectively, in schedule-fed rats. Amylin also reduced water intake to a much lesser degree in 24-h water-deprived rats. A test of the ability of AMY to form a conditioned taste aversion yielded no change in saccharin preference, as compared to controls treated with vehicle. These results suggest that although AMY has adipsic effects, the reduction in water is not of sufficient magnitude to cause the anorexia. In addition, the failure of AMY to support a conditioned taste aversion suggests that AMY does not cause anorexia by inducing malaise. Therefore, in addition to other metabolic effects, AMY may be involved in the control of food and water intake.

Citing Articles

Fluid intake, what's dopamine got to do with it?.

Mietlicki-Baase E, Santollo J, Daniels D Physiol Behav. 2021; 236:113418.

PMID: 33838203 PMC: 8900711. DOI: 10.1016/j.physbeh.2021.113418.


Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases.

Sonne N, Karsdal M, Henriksen K Mol Metab. 2020; 46:101109.

PMID: 33166741 PMC: 8085567. DOI: 10.1016/j.molmet.2020.101109.


Endogenous VMH amylin signaling is required for full leptin signaling and protection from diet-induced obesity.

Dunn-Meynell A, Le Foll C, Johnson M, Lutz T, Hayes M, Levin B Am J Physiol Regul Integr Comp Physiol. 2015; 310(4):R355-65.

PMID: 26676252 PMC: 4868368. DOI: 10.1152/ajpregu.00462.2015.


Amylin activates distributed CNS nuclei to control energy balance.

Mietlicki-Baase E, Hayes M Physiol Behav. 2014; 136:39-46.

PMID: 24480072 PMC: 4113606. DOI: 10.1016/j.physbeh.2014.01.013.


GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Roth J, Erickson M, Chen S, Parkes D Br J Pharmacol. 2011; 166(1):121-36.

PMID: 21671898 PMC: 3415643. DOI: 10.1111/j.1476-5381.2011.01537.x.